Clinical Trials
Pegylated Interferon Alfa-2b
Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia ClinicalTrials.gov ID NCT05395507 Sponsor Institute of Hematology & Blood Diseases Hospital, China
Clinical Trials
Clinical Trials
Recombinant Interleukin-15
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers ClinicalTrials.gov ID NCT03388632 Sponsor National Cancer Institute (NCI) Information provided by National Institutes of Health Clinical Center (CC) (National Cancer Institute (NCI)) (Responsible Party)
Clinical Trials
Role of IL-5R Signaling
Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP (RECAP-5) ClinicalTrials.gov ID NCT05672030 Sponsor Brigham and Women’s Hospital Information provided by Tanya Laidlaw, MD, Brigham and Women’s Hospital (Responsible Party)
Clinical Trials
Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia
ClinicalTrials.gov ID NCT05600920 Sponsor National Institute of Allergy and Infectious Diseases (NIAID) Information provided by National Institutes of Health Clinical Center (CC) (National Institute of Allergy and Infectious Diseases (NIAID)) Study Overview Brief Summary Background: Idiopathic CD4 lymphopenia (ICL) is a syndrome characterized by low levels of certain immune cells [READ MORE]
Clinical Trials
Serum IL 26 as a Marker of Disease Activity in SLE
ClinicalTrials.gov ID NCT05161988 Sponsor: Assiut University Information provided by Fatma alzahraa Mustafa Abdelbary Thabet, Assiut University (Responsible Party) Study Overview Brief Summary Assessment of serum Interleukin 26 level in SLE patients and compare it with healthy controls. Association of serum interleukin 26 with SLE activity and severity. Detailed Description Systemic [READ MORE]
Clinical Trials
Cancer Ratio,Pleural Fluid Adenosine Deaminase,Lactate Dehydrogenase, interferonY, Tumor Necrosis Factor,and Interleukins{2,12,18}for Differentiation Between Malignant and Non Malignant Pleural Effusion
ClinicalTrials.gov ID NCT05693727 Sponsor: Assiut University Information provided by Mona Adel, Assiut University (Responsible Party) Study Overview Brief Summary To evaluate the ability of cancer ratio and pleural fluid markers to discriminate between malignant and non malignant effusion Detailed Description Pleural effusion is a common clinical entity affecting approximately 1.5 [READ MORE]
Clinical Trials
Clinical Trials – updated December 18, 2024
1) Estimation of the Tissue and Serum Levels of Interleukin (IL) -35 in Mycosis Fungoides: a Case Control Study | 2) Impact of Smoking on Salivary Interleukin (IL)-39, IL-41, IL-1β, TNF-α Levels in Periodontal Disease | 3) Targeting IL-17A for Treatment-Resistant Depression [READ MORE]
Clinical Trials
Clinical Trials – updated November 20, 2024
1) Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis (ClinicalTrials.gov ID NCT05309616) | 2) Assessment of Serum interleukin10 Level in Patients With Immune Thrombocytopenic Purpura at Sohag University Hospital (ClinicalTrials.gov ID NCT05835050) | 3)Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma (DiTuSarc) (ClinicalTrials.gov ID NCT05080790) [READ MORE]
Clinical Trials
Clinical Trials for the week of November 6
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
New CSF Biomarkers for Alzheimer’s Disease (BioAD)
Interleukin and Autoantibodies in Myasthenia Gravis [READ MORE]
Clinical Trials
Clinical Trials for the week of October 16
CSF Protein Markers as Prognostic Indicators of the Response to CSF Shunt in Normotensive Hydrocephalus | GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study (GRACE) | Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease (GPAD-3) [READ MORE]